Trial Profile
A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 598809 (Primary)
- Indications Eating disorders; Obesity
- Focus Pharmacodynamics
- Sponsors GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 12 Jul 2011 Results published in the International Journal of Neuropsychopharmacology.
- 13 Aug 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.